Bringing the fundamentals into focus…
Back to NeoGenomics, Inc.
How NeoGenomics, Inc. stacks up
NEO · against 1,336 other Healthcare companies
Valuation
31/ 100
Below the middle of the pack.
Ranked #917 of 1,337 · scores higher than 31% of peers
Bars: peers in each 10-point band of the valuation score133 peers with a valuation score of 30–39, including NEO · Click a bar to see the companies
Why valuation scores 31?
Weighted metrics compared with all Healthcare companies.Mainly because of its earnings yield and EBITDA yield, which are weaker than most Healthcare peers.
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Earnings yield: -2.4% vs peer median 1.5%
- less operating profit (EBITDA) for the company's total value: weaker than 65% of peers. EBITDA yield: 1.0% vs peer median 4.0%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Free cash flow yield: -0.3% vs peer median 0.0%
Metric by metric
Position: dot = NEO, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | NEO | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 1,287 reported | -2.3% | 1.5% | 33% | 30% | |
| EBITDA yieldHigher is better · 1,357 reported | 1.0% | 4.2% | 35% | 50% | |
| Free cash flow yieldHigher is better · 711 reported | -0.3% | -1.0% | 52% | 20% | |
| Book yieldHigher is better · 1,306 reported | 36.5% | 37.9% | 49% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around NEOScores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score